On December 4, 2020, StageZero Life Sciences Ltd. (“StageZero”) (TSX: SZLS) announced that it closed its previously announced public offering of 9,243,700 units (the “Units”) raising aggregate gross proceeds of $7,210,086 (the “Offering”). Each Unit was comprised of one common share and one-half of one common share purchase warrant.
StageZero was represented by WeirFoulds, with a team consisting of Rob Eberschlag, Conor Dooley, Alvin Yau, Ryan Morris and Ann Lattanzio.
StageZero is dedicated to the early detection of multiple disease states through whole blood. The company operates a CAP accredited and CLIA certified high complexity reference laboratory based in Richmond, Virginia. As a specialist in PCR testing for the early identification of Cancer through blood, the company is uniquely positioned to provide both COVID-19 PCR testing (swab and saliva) and blood test analysis (antibody testing).
WeirFoulds is pleased to have assisted StageZero in the closing of this financing.
To learn more about our Securities Practice Group or to contact one of our securities lawyers, visit our securities practice group overview page.
